You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lenvatinib

Showing 26 - 50 of 454
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Kaposi Sarcoma, Classic Kaposi Sarcoma, Refractory Kaposi Sarcoma Trial (Pembrolizumab + Lenvatinib)

Not yet recruiting
  • Kaposi Sarcoma
  • +2 more
  • Pembrolizumab + Lenvatinib
  • (no location specified)
Apr 27, 2023

Efficacy of Lenvatinib in Differentiated Thyroid Cancer

Recruiting
  • Differentiated Thyroid Cancer
  • Gender
  • Lenvatinib
  • Rome, Italy
    Regina Elena National Cancer Institute
Mar 16, 2023

Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +5 more
  • TACE
  • Tislelizumab, Lenvatinib
  • Hangzhou, Zhejiang, China
    1# Banshan East Rd. Zhejiang cancer hospital
Jun 17, 2023

Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • +3 more
  • Lenvatinib/Pembrolizumab plus SBRT combinations
  • Taipei City, Taiawn, Taiwan
    National Taiwan University Hospital
Jan 30, 2023

Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)

Recruiting
  • Biliary Tract Neoplasms
  • Immunotherapy
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Jul 6, 2023

Renal Cell Carcinoma Trial in Guangzhou (Pucotenlimab Combined With Lenvatinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • Pucotenlimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 10, 2023

Advanced Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cryoablation, Sintilimab, Lenvatinib)

Recruiting
  • Advanced Intrahepatic Cholangiocarcinoma
  • Cryoablation
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 28, 2023

Fumarate Hydratase Deficient Renal Cell Carcinoma Trial (Tislelizumab, Lenvatinib)

Not yet recruiting
  • Fumarate Hydratase Deficient Renal Cell Carcinoma
  • Tislelizumab
  • Lenvatinib
  • (no location specified)
May 18, 2023

Solid Tumors Trial in Chongqing (F520, Lenvatinib)

Recruiting
  • Solid Tumors
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Feb 13, 2023

Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer Trial (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Recurrent Vulvar Cancer
  • +3 more
  • (no location specified)
Jun 12, 2023

Gastric / Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (envafolimab and lenvatinib combined with

Enrolling by invitation
  • Gastric / Gastroesophageal Junction Adenocarcinoma
  • envafolimab and lenvatinib combined with paclitaxel-albumin
  • Shanghai, Shanghai, China
    Fudan University Cancer Hospital
Sep 3, 2023

Renal Cell Carcinoma Trial in Philadelphia (Pembrolizumab infusion, Lenvatinib tablet)

Not yet recruiting
  • Renal Cell Carcinoma
  • Pembrolizumab infusion
  • Lenvatinib tablet
  • Philadelphia, Pennsylvania
    Abramson Cancer Center at University of Pennsylvania
Feb 8, 2023

Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

Recruiting
  • Advanced Biliary Tract Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 22, 2023

Hepatocellular Carcinoma Trial in Taoyuan (ADI-PEG20)

Recruiting
  • Hepatocellular Carcinoma
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou branch
Sep 6, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Hepatocellular Carcinoma Trial (Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
  • (no location specified)
Jun 12, 2023

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 13, 2022

Cervical Cancer, Cervical Carcinoma Trial in Guangzhou (Zimberelimab, Lenvatinib)

Not yet recruiting
  • Cervical Cancer
  • Cervical Carcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Renal Cell Carcinoma Trial (Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy,

Not yet recruiting
  • Renal Cell Carcinoma
  • Neoadjuvant Lenvatinib
  • +3 more
  • (no location specified)
Dec 23, 2022

Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer Trial in Tampa (Pembrolizumab, Lenvatinib)

Active, not recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 24, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin Trial in Tampa (Lenvatinib Oral

Recruiting
  • Merkel Cell Carcinoma
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Lenvatinib
  • +2 more
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Oct 20, 2022

Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Adjuvant tislelizumab plus lenvatinib
  • Adjuvant tislelizumab
  • Nanning, China
    Jian-Hong Zhong
Jun 11, 2023

Hepatocellular Carcinoma Trial (Oncorine, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Jan 30, 2023